第1章 簡介

第2章 市場概要

第3章 市場決策因素

推動市場的要素

阻礙市場的要素

市場機會

市場課題

第4章 市場區隔

產品與服務

各技術

各適應症

各終端用戶

第5章 競爭環境

主要策略

合併·收購

合資企業

產品上市

聯盟

第6章 各地區分析

支持決策的資料庫與預測技術

比較分析

機會矩陣

各地區市場

北美

歐洲

亞太地區

其他各國

第7章 企業簡介

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Product Code: HAD-8431117

The global companion diagnostics market is expected to grow at a CAGR of over 20.1% during the period of 2016-2023. Companion diagnostic tests are used for collecting patient information, dosing requirement, and susceptibility regarding the side effects of any particular drug. Companion diagnostics tests are also known as pharmacogenetic tests. While many drug labels provide guidance on pharmacogenetic testing, certain drugs specifically cancer drugs, require patients to receive a diagnostic test, as the efficacy of these drugs is limited to those with a particular genotype. Major driving forces of companion diagnostics are improved regulatory guidelines, rising cancer incidence across the globe, need for targeted therapies, and increasing collaborations and partnerships for test development. The companion diagnostics market is fastest growing segments of the IVD and clinical lab services markets. United States, over half of all FDA approvals for companion diagnostics have occurred since 2010. The closely associated pharmacodiagnostics IVD market is expected to grow annually by over 20%. Approval of CDX- assisted therapies, and high growth of market opened for laboratory tests and IVD products. Global companion diagnostics is facing challenges as prolonged development time of companion diagnostics, increasing duration of the approval, in spite of all challenges there are huge opportunities as process increasing new indication areas, increasing demand for next-generation sequencing, increasing number of clinical trials which will leverage the market of data fabric.

The global companion diagnostics market is segmented on the basis of product & services, indication, technology and end user. Indication segment consist of oncology, cardiovascular conditions, central nervous system indications, inflammation and virology segment. Oncology is dominating the indication segment. Technology market is segmented as Immunohistochemistry and Molecular diagnostics etc. Molecular diagnostics is the fastest growing and highest revenue generator product & service segment consist of assay kits, reagents, and software & services. End user segment of market is differentiate into pharmaceutical & biopharmaceutical companies, reference laboratories, and other end users. The pharmaceutical and biopharmaceutical companies segment is dominating the market during the forecasted period.

Geographically North America hold the largest share in companion diagnostics market, due to the high technological advancements in the region. Asia Pacific market is expected to grow at the highest CAGR between 2016 and 2023. The primary forces which are driving growth of the market are the growing prevalence diseases like cancer and neurology diseases, also increasing number of hospitals and diagnostics laboratories are creating huge opportunity which is driving the growth of the companion diagnostics market.

The growth in global companion diagnostics market is also influenced by the presence of major players such Qiagen n.v. (Netherland), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Genomic Health, Inc. (US) and other. Collaborations and partnership etc. are some crucial strategies adopted by the major players to gain competitive advantage.

Table of Contents

1. INTRODUCTION

1.1. EXECUTIVE SUMMARY

1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

2.1. GLOBAL COMPANION DIAGNOSTIC MARKET: EVOLUTION & TRANSITION

2.2. MARKET DEFINITION & SCOPE

2.3. INDUSTRY STRUCTURE

2.4. TOTAL MARKET ANALYSIS

2.4.1. TOP 5 FINDINGS

2.4.2. TOP 5 OPPORTUNITY MARKETS

2.4.3. TOP 5 COMPANIES

2.4.4. TOP 3 COMPETITIVE STRATEGIES

2.5. ESTIMATION ANALYSIS

2.6. STRATEGIC ANALYSIS

2.6.1. INVESTMENT VS. ADOPTION MODEL

2.6.2. 360-DEGREE INDUSTRY ANALYSIS

2.6.3. PORTERS 5 FORCE MODEL

2.6.4. SEE-SAW ANALYSIS

2.6.5. ROI ANALYSIS

2.6.6. GAP ANALYSIS

2.6.7. PATENT ANALYSIS

2.6.8. PRICING ANALYSIS

2.6.9. PIPELINE ANALYSIS

2.6.10. CONSUMER ANALYSIS AND KEY BUYING CRITERIA

2.7. COMPETITIVE ANALYSIS

2.7.1. KEY STRATEGIES & ANALYSIS

2.7.2. MARKET SHARE ANALYSIS AND TOP MARKET ANALYSIS

2.8. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS

2.8.1. INVESTMENT OPPORTUNITIES BY REGIONS

2.8.2. OPPORTUNITIES IN EMERGING APPLICATIONS

2.8.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

3.1. MARKET DRIVERS

3.1.1. IMPROVEMENTS IN REGULATORY GUIDELINES

3.1.2. GROWING NEED FOR TARGETED THERAPIES

3.1.3. RISING CANCER INCIDENCE ACROSS THE GLOBE

3.1.4. INCREASING PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS TEST DEVELOPMENT